3 Overrated Stocks We Approach with Caution
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
While momentum can be a leading indicator, it has burned many investors as it doesn’t always correlate with long-term success. Keeping that in mind, here are three stocks getting more buzz than they deserve and some you should buy instead.
Proto Labs (PRLB)
One-Month Return: +20.1%
Pioneering the concept of online quoting and manufacturing for custom prototypes and low-volume production parts, Proto Labs (NYSE:PRLB) offers injection molding, 3D printing, and sheet metal fabrication for manufacturers in various industries.
Why Are We Hesitant About PRLB?
- Muted 4.4% annual revenue growth over the last five years shows its demand lagged behind its industrials peers
- Poor expense management has led to an operating margin of 0.6% that is below the industry average
- Push for growth has led to negative returns on capital, signaling value destruction
Proto Labs’s stock price of $94.38 implies a valuation ratio of 41.5x forward P/E. To fully understand why you should be careful with PRLB, check out our full research report (it’s free).
Solventum (SOLV)
One-Month Return: -4.5%
Founded in 1985, Solventum (NYSE:SOLV) develops, manufactures, and commercializes a portfolio of healthcare products and services addressing critical customer and therapeutic patient needs.
Why Does SOLV Give Us Pause?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Sales are projected to be flat over the next 12 months and imply weak demand
- Free cash flow margin shrank by 18.2 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
Solventum is trading at $87.76 per share, or 13x forward P/E. Dive into our free research report to see why there are better opportunities than SOLV.
Novavax (NVAX)
One-Month Return: +3.5%
Pioneering a nanoparticle technology that mimics the molecular structure of disease pathogens, Novavax (NASDAQ:NVAX) develops and commercializes protein-based vaccines for infectious diseases, with a primary focus on its COVID-19 vaccine and combination respiratory vaccine candidates.
Why Are We Out on NVAX?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 18.9% annually over the last five years
- Overall productivity fell over the last two years as its plummeting sales were accompanied by a decline in its adjusted operating margin
- Cash burn makes us question whether it can achieve sustainable long-term growth
At $10.68 per share, Novavax trades at 7.4x forward price-to-sales. Check out our free in-depth research report to learn more about why NVAX doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.